Molecular epidemiology of HIV-1 in central region of Nepal Nirajan Bhusal 1,2, Navin Horthongkham 1, Niracha Athipanyasilp 1, Wannee Kantakamalakul 1,

Slides:



Advertisements
Similar presentations
Solange Arazi Caillaud. MD Emiliano Bissio. MD María Ester Lázaro. MD.
Advertisements

Emerging patterns of drug resistance and viral tropism in cART-naïve and failing patients infected with HIV-1 subtype C Thumbi Ndung’u, BVM, PhD Associate.
An epidemic in transition: impacts of migration and local networks on HIV sequence diversity and infection transmission in Australia
Virologic and immunologic response following antiretroviral therapy initiation among pregnant and postpartum women with acute HIV-1 infection: MOPDB0101.
HIV Infection in Michigan January 1, 2012 Michigan Department of Community Health HIV/STD/VH/TB Epidemiology Section Division of Communicable Diseases.
Dr Emmanuel Nsutebu Consultant Infectious Diseases Physician Tropical and Infectious Diseases Unit Royal Liverpool Hospital HIV “Myths, controversies and.
Phase 2 of new ARVs BMS (maturation inhibitor)
An Introduction to the HIV Problem Space Oakwood University: Faculty Quantitative Institute Aug. 10–12, 2009.
ACTG 333 The Antiviral Effect of Switching from Saquinavir to the New Formulation of Saquinavir vs. Switching to Indinavir After >1 year of Saquinavir.
1 HIV/STD Trends in Texas Sharon K. Melville, M.D., M.P.H. Texas Department of State Health Services Texas Public Health Association April 22, 2010.
2012 HIV/AIDS surveillance in Europe European Centre for Disease Prevention and Control, Stockholm WHO Regional Office for Europe, Copenhagen.
Emerging Trends of HIV/AIDS in New York City Chris Williams, MPH NYC DOHMH.
Persisting long term benefit of genotypic guided treatment in HIV infected patients failing HAART and Importance of Protease Inhibitor plasma levels. Viradapt.
HIV/AIDS Epidemiology Update February 2009 Dr Nigel Dickson Director, AIDS Epidemiology Group Department of Preventive and Social Medicine University of.
HIV/AIDS in Michigan January 1, 2010 Michigan Department of Community Health HIV/STD/VH/TB Epidemiology Section Division of Communicable Diseases Bureau.
AIDS Epidemic and Control in China Zeng Yi Chinese Foundation for Prevention of STD and AIDS.
Using Phylogenetic Analysis to Identify HIV Transmission Channels among Persons Newly Diagnosed with HIV-1 Infection in Los Angeles County, Kwa.
Wisconsin Department of Health Services HIV/AIDS Surveillance Annual Review New diagnoses, prevalent cases, and deaths through December 31, 2013 April.
Phylogenetic Insight into HIV Transmission Networks in a Southeastern US Cohort Ann Dennis 1, Stéphane Hué 2, Christopher Hurt 1, Sonia Napravnik 1, Deenan.
Background There is uncertainty regarding the frequency, predictors, and outcomes of IRIS events Prior studies on IRIS have been limited to convenience.
Global HIV Resistance: The Implications of Transmission
HIV Care Continuum, District 8- 2 Southwest (Albany), Georgia, 2012.
Phylogenetic analysis of HIV-1 Gag cleavage sites polymorphism in HIV acutely infected patients Castro E 1,2, Cavassini M 1, Bart PA 2 and Pantaleo G 2.
Predicting NNRTI Resistance – do polymorphisms matter? Nicola E Mackie 1, Lucy Garvey 1, Anna Maria Geretti 2, Linda Harrison 3, Peter Tilston 4, Andrew.
Life expectancy of patients treated with ART in the UK: UK CHIC Study Margaret May University of Bristol, Department of Social Medicine, Bristol.
Quarterly HIV/AIDS Analysis for Michigan January 1, 2008 Michigan Department of Community Health HIV/STD/Viral Hepatitis and TB Epidemiology Section Division.
HIV Care Continuum, Georgia, United States, 2011 Presented to American Public Health Association, Annual Meeting Presented by Deepali Rane, MBBS, MPH,
HBV related complications in HIV positive patients during HAART therapy Irina Magdalena Dumitru*, E. Dumitru*, S. Rugina*, Roxana Carmen Cernat**, Simona.
AIDS Epidemic Update December /06 e. AIDS Epidemic Update December /06 e TOTAL North America Eastern Europe & Central Asia Latin America.
Primary HIV-1 drug resistance in Canada: Updated results from the Canadian HIV Strain and Drug Resistance Surveillance Program Canadian HIV Strain and.
HIV Care Continuum, District 10 Northeast (Athens), Georgia, 2012.
HIV Care Continuum Persons Living With HIV, Georgia, 2012.
HIV/AIDS in Istanbul Dr.Mucahit Yemisen Cerrahpasa Medical School, Department of Infectious Diseases.
SOUTH CAROLINA EPIDEMIOLOGIC PROFILE What is the Epi Profile? The HIV/AIDS Epidemiologic Profile is a document that: Describes the HIV/AIDS epidemic.
High Discordance in Plasma and Genital Tract HIV-1 Drug Resistance in Indian Women Failing First-line Therapy MOPDA0106 S. Saravanan, PhD Session Code:
Transmitted drug resistance Pat Cane. Questions What is the level of TDR and is it changing? Are we measuring TDR accurately? Are more sensitive methods.
Ministry of Health Health Surveillance Secretariat NATIONAL STD/AIDS PROGRAMME.
Integration of collaborative TB/HIV activities with harm reduction services Maryna Zelenskaya Ph D State service on HIV/AIDS and other socially diseases.
Annual Epidemiological Spotlight on HIV in London: 2014 data Field Epidemiology Services PHE Publications gateway number
Mean HIV viral load among resident cases and undiagnosed in Oregon Jeff Capizzi, Epidemiologist Sean Schafer, HIV/STD/TB Medical Epidemiologist Lea Bush,
00002-E-1 – 1 December 2001 Global summary of the HIV/AIDS epidemic, December 2001 Number of people living with HIV/AIDS Total40 million Adults37.2 million.
Chicago Department of Public Health Richard M. Daley Mayor Bechara Choucair, MD Commissioner CDPH – STI/HIV Surveillance, Epidemiology and Research Section.
Strategies for Management of Antiretroviral Therapy Study Wafaa El-Sadr and James Neaton for the SMART Study Team.
00002-E-1 – 1 December 2002 Global summary of the HIV/AIDS epidemic, December 2002 Number of people living with HIV/AIDS Total42 million Adults38.6 million.
Phar. Nhat Mang/ Roche Vietnam
Viral load distribution 2012 among persons living with HIV and persons newly diagnosed Georgia, 2011.
HIV and AIDS Data Hub for Asia-Pacific HIV and AIDS Data Hub for Asia-Pacific Review in slides Thailand.
Evolution and transmission in HIV Steve Paterson Review; Rambaut 2004 Nature Reviews Genetics 5: ‘The causes and consequences of HIV evolution’
Serologic markers and molecular epidemiology of HBV from an HIV infected cohort from Cameroon Tshifhiwa Magoro 1, Emmaculate Nongpang 2, Lufuno Mavhandu.
Prospective Observational European Study of the natural history and Treatment of Syphilis in HIV positive individuals – The POETS Study Rowley D 1, Fätkenheuer.
00002-E-1 – 1 December 2001 THE HIV/AIDS PANDEMIC Focus on Africa By Dr. David Elkins HIV/AIDS Prevention and Care Project Nairobi, Kenya September 2002.
Notified AIDS and HIV Infection Cases in the Seychelles: Epidemiological Trends Ministry of Health, SeychellesMinistry of Health, Seychelles –N. E. Udonwa.
Copyright © 2016, 2013, 2010 by Saunders, an imprint of Elsevier Inc. All rights reserved. Chapter 94 Antiviral Agents II: Drugs for HIV Infection and.
HIV Epidemic in Malaysia. HIV BY AGE GROUPS - MALAYSIA.
Summary of HIV Infection in Alaska, 1982–2015 Prepared by the State of Alaska Department of Health and Social Services, Division of Public Health, HIV/STD.
undetectable (undetectable-6.25)
Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort.
Etravirine versus Protease Inhibitor in ARV-Experienced TMC 125-C227
HIV/AIDS Surveillance in Europe 2011 HIV/AIDS surveillance in Europe
Introduction Results Objectives Methods Conclusion Funding
HIV in Ireland Quarter 1& Provisional Data 15th November 2017
Latest update to the National Outbreak Response group on recent trends in HIV, STIs and Hepatitis among men who have sex with men (MSM) in Ireland June.
HIV/AIDS Surveillance in Europe 2011 HIV/AIDS surveillance in Europe
HIV/AIDS Surveillance in Europe 2011 HIV/AIDS surveillance in Europe
Health Protection Surveillance Centre
Frequency and implications of HIV superinfection
Evolution and transmission in HIV
Global estimates for adults and children, 2014
ANTIRETROVIRAL RESISTANCE IN CLINICAL PRACTICE
Share your thoughts on this presentation with #IAS2019
Presentation transcript:

Molecular epidemiology of HIV-1 in central region of Nepal Nirajan Bhusal 1,2, Navin Horthongkham 1, Niracha Athipanyasilp 1, Wannee Kantakamalakul 1, Ruengpung Sutthent 1 1 Department of Microbiology, Faculty of Medicine Siriraj hospital, Mahidol University, Thailand. 2 Department of Microbiology, Kathmandu University School of Medical Sciences, Kavre, Nepal

data sources:AIDSinfoonline.org Trend of global HIV Infection and Death

HIV Prevalence:

Subtypes and CRFs distribution in Asia:

Epidemic snapshot of HIV in Nepal

Subjects

Clinical characteristics of selected sample Sample I.DYear of Infection Location Risk GroupViral loadART status NP Nawalparasi HSR3,685NONE NP Chitwan HSR79,787AZT,3TC,NVP NP Nawalparasi HSR5,942NONE NP Chitwan IDU3,298AZT,3TC,NVP NP parsa MTCT31,940NONE NP Chitwan HSR10,413AZT,3TC,NVP NP Chitwan HSR5,942AZT,37C,NVP NP Chitwan HSR63,485NONE NP Chitwan HSR14,420AZT,3TC,NVP NP Gorkha HSR4,599AZT,3TC,EFV NP Chitwan HSR22,777AZT,3TC,NVP NP Makwanpur HSR< 40AZT,3TC,NVP NP Chitwan MTCT8,64,318d4T,3TC,EFV NP Chitwan IDU4,599AZT,3TC,NVP NP Chitwan IDU40,192NONE NP Chitwan HSR159,488AZT,3TC,NVP NP Chitwan IDU25,980AZT,3TC,NVP NP Chitwan MSM2,176NONE NP Gorkha HSR2,230NONE NP Chitwan MTCT6,067NONE NP Chitwan IDU51,218AZT,3TC,NVP NP Nawalparasi HSR86,103AZT,3TC,NVP NP Nawalparasi HSR7,314NONE NP Nawalparasi HSR9,649NONE NP Chitwan MTCT3,186NONE

Sample I.DYear of Infection Location Risk GroupViral loadART status NP Chitwan HSR9,649NONE NP Nawalparasi HSR21,253NONE NP Nawalparasi HSR32,235NONE NP Chitwan HSR44,285NONE NP Parsa HSR4,695 AZT,3TC,NVP NP Chitwan HSR60,480NONE NP Chitwan HSR3,535NONE NP Nawalparasi MSM21,265AZT,3TC,NVP NP Chitwan HSR5,545NONE NP Chitwan HSR<40AZT,3TC,EFV NP Nawalparasi MSM1,819NONE NP Nawalparasi MTCT9,625NONE NP Chitwan HSR5,807NONE NP Nawalparasi HSR31,794AZT,3TC,NVP NP Chitwan HSR2,612AZT,3TC,NVP NP Chitwan HSR159,488NONE NP Chitwan IDU25,980AZT,3TC,NVP NP Chitwan HSR2,176NONE NP Gorkha HSR2,230AZT,3TC,NVP NP Chitwan MSM6,067NONE NP Chitwan HSR51,218NONE NP Nawalparasi HSR86,103AZT,3TC,NVP NP Nawalparasi HSR7,314NONE NP Nawalparasi HSR9,649NONE NP Chitwan MTCT3,186NONE Clinical characteristics of selected sample

Siriraj hospital in bangkok

Ethical issues

Characteristics Total patientsART Naïve patientsART experienced n n n Number of patients1073 Male642 Female431 Transmission mode Heterosexual541 Homosexual110 MTCT211 IDU211 medianmin-maxmedian Age (years) CD4 + T cells Viral load (log copies/ml) –

Phylogenetic analysis of 10 HIV-1 nearly full length nucleotide sequences

9 samples : 11NP004,11NP014, 11NP016, 11NP065, 11NP076, 11NP084, 11NP086, 11NP091 and 11NP115 1 sample 11NP079

Fragment Start Position Uncertainty Region Start - End Breakpoint Interval Start - End Fragment End PositionFragment Subtype Position in the original sequence [pred_recombinati on], [recombination_incl_UR _and_BPI], [UR_and_BPI][pred_recombinati on][recombination_incl_UR _and_BPI][UR_and_BPI] N/A C D C D C N/A Position based on HXB2 numbering [pred_recombinat ion] [recombination_incl_UR _and_BPI] [UR_and_BPI]HXB2 numbering[pred_recombinat ion][recombination_incl_UR _and_BPI][UR_and_BPI]

Sample ID HIV diagnosis year Route of infection Plasma HIV-1 RNA level (copies/ml) HIV DRM PI NRTI NNRTIDrugs 11NP MTCT31,940--K103R Efavirenz 11NP HSR10,413--V179D Delavirdine 11NP HSR2,230--E138A Etravirine 11NP IDU51,218--K103R Efavirenz 11NP822010HSR32,325A71V-- Ritonavir 11NP HSR2,612A71T-- Indinavir 11NP MTCT159,297--V108I Efavirenz 11NP MSM58,782A71T-- Mutation pattern of amino acids and drug resistance

Subtype C NP015 one major mutation at position 82 one minor at 60 CRF-08BC NP008 three minor mutation at position 36,60 and 77 Position B-cons T V L E E M N L P G R W K P K M I G G I G G F I K V R Q Y D C-cons..... V S... K. R E NP D I D Q NP N D H Position B-cons A I G T V L V G P T P V N I I G R N L L T Q I G C T L N F C-cons M NP I NP I Amino acid polymorphism in different subtypes

Signature sequence pattern analysis NP003- HSRT C T R P S N N T R K S I I G P G Q T F Y NP131- MSMN.... N NP003- HSRA T G D I I G D I R Q A H C N I NP131- MSM A V NP003-HSRT C T R P S N N T R K S I I G P G Q T F Y NP128-MTCTN Q R A NP003- HSRA T G D I I G D I R Q A H C N I NP128-MTCT E.. K.....

NP003-HSRT C T R P S N N T R K S I I G P G Q T F Y NP041-IDUV. I.. N NP003-HSRA T G D I I G D I R Q A H C N I NP041-IDU Signature sequence pattern analysis 9 variable positions amino acid sequences between different risk groups All risk group had GPGQ pattern at v3 loop.